In Cell Art: Towards innovative vaccines
Published on 13 January 2017
The start-up company was founded in 2005, by a team of researchers including Jean-Marie Lehn, a Nobel laureate in chemistry and Bruno Pitard from Nantes University (CNRS 6291 / Inserm1087), who began his career at Sanofi. The company carries on with its growth, while maintaining its local base. After 10 years, the company is still owned by its founders, and is seeking between 3 and 4 million euros in order to produce innovative vaccines using its Nanotaxi® technology *. Read more